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Abstract: Bupropion has been used as an antidepressant for over twenty years, though its 
licence for such use varies and it is typically a third- or fourth-line agent. It has a unique 
pharmacology, inhibiting the reuptake of noradrenaline and dopamine, potentially providing 
pharmacological augmentation to more common antidepressants such as SSRIs. This 
systematic review and meta-analysis identified 51 studies, dividing into four categories: 
bupropion as a sole antidepressant, bupropion co-prescribed with another antidepressant, 
bupropion in ‘other’ populations (e.g. bipolar depression, elderly populations), and primary 
evaluation of side effects.   
Methodologically more robust trials support bupropion’s superiority over placebo, and most 
head-to-head antidepressant trials showed an equivalent effectiveness, though some of 
these are hindered by a lack of a placebo arm. Most work on the co-prescribing of 
bupropion with another antidepressant support an additional effect, though many are 
open-label trials. Several large multi-medication trials – most notably STAR*D – also support 
a therapeutic role for bupropion; in general it had a similar effectiveness to other 
medications, though this literature highlights the generally low response rates in refractory 
cohorts. Effectiveness has been shown in ‘other’ populations, though there is an overall 
dearth of research. Bupropion is generally well tolerated, and it has very low rates of sexual 
dysfunction, and is more likely to cause weight loss than gain.  
Our findings support the use of bupropion as a sole or co-prescribed antidepressant, 
particularly if weight gain or sexual dysfunction are, or likely to be, significant problems. 
However there are notable gaps in the literature, including less information on treatment 
naïve and first presentation depression – particularly when one considers the ever reducing 
rates of response in more refractory illness. There are some data to support bupropion 
targeting specific symptoms, but insufficient information to reliably inform prescribing, and 
it remains uncertain if bupropion pharmacodynamically truly augments other drugs.   
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Introduction 
Major depressive disorders (MDD) are a leading global cause of morbidity (Ferrari et al., 
2013; Kessler et al., 2003; Murray et al., 2013) affecting up to a fifth of individuals 
(Hirschfeld, 2012), four fifths of whom will have multiple illness episodes (Bulloch, Williams, 
Lavorato, & Patten, 2014).  
Guidelines generally advocate Selective Serotonergic Reuptake Inhibitors (SSRIs) as the first-
line pharmacological intervention, primarily due to their more benign side-effect profile 
rather than any superiority in efficacy (NICE, 2009). A so-called “therapeutic trial” of a 
minimum recognised dose over about six weeks is ordinarily recommended before changing 
medication, and treatment resistance is usually defined as failure to respond to two such 
trials. Disappointing data indicate that about half of patients discontinue their treatment 
during such an initial time frame (Melfi et al., 1998). 
Response, typically defined as a ≥50% symptom reduction, is typically seen in about half to 
three quarters on a first trial of an antidepressant, with symptom remission occurring in 
about a third (Nemeroff et al., 2008; Trivedi, Rush, et al., 2006). Unfortunately many 
individuals prove resistant to multiple first and second line pharmacological interventions 
(Coplan, Gopinath, Abdallah, & Berry, 2014; Rush et al., 2004). Treatment options thereafter 
include changing drug class or adding a second agent, though there are not convincing data 
to clearly support one strategy over the other (Rush, 2007); the overall literature on 
pharmacological ‘next-steps’ has numerous options, but most without strong evidence 
bases (Taylor, Paton, & Kapur, 2015). 
Most antidepressants act through increasing the synaptic levels of serotonin and/or 
noradrenaline (norepinephrine) through various pharmacological mechanisms. Bupropion is 
an aminoketone, and has a unique pharmacology, inhibiting the reuptake of both 
noradrenaline and dopamine. It has no effects on serotonin, histamine, acetylcholine, or 
adrenaline (epinephrine) receptors; it is thus not associated with significant sedation, 
cognitive or anticholinergic gastrointestinal, or hypotensive side effects (Stahl et al., 2004). 
Bupropion has been licensed for depression in the United States since the late 1990s (Fava 
et al., 2005); an extended formulation version became available in 2007. In the United 
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Kingdom it is only licensed for the treatment of nicotine addiction, though it is prescribed 
off-licence for depression. There is literature to supporting its effectiveness as an 
antidepressant in various populations, and data that it can cause weight loss and help sexual 
dysfunction. However to date there have been no systematic reviews or meta-analyses of its 
effectiveness and side effect profile in affective disorders. 
 
Aims 
To systematically evaluate and meta-analyse the effectiveness of bupropion as an 
antidepressant, both when prescribed alone, and in combination with other 
antidepressants, and its side-effect profile, particularly effects on weight and sexual 
dysfunction. 
 
Methods 
Search Strategy. An electronic search was conducted between March 19, 2015 and March 
27, 2015. Potentially relevant studies were identified by searching the following databases: 
PsycInfo ((1806 – 2015, March 27) / Medline (1946 to 2015, March 27) / Embase (1980 to 
2015, March 27)) via OvidSP, PubMed, Web of Science (Core Collection), and The Cochrane 
Library. The search criteria were as follows: “bupropion” OR “Wellbutrin” OR “Aplenzin” OR 
“Forfivo” OR “Zyban” OR “Amfebutamone” combined with AND “major depress*” OR 
“(MDD)” OR “depress*” OR “mood disorder” OR “depressive-disorder” OR “bipolar” OR 
“unipolar” OR “bipolar affective disorder” OR “seasonal affective disorder”. The review was 
limited to articles published in English, and a thorough search of grey literature was not 
undertaken. The reference list of each included study and relevant reviews were examined 
for potential studies. 
Participants. Studies that looked at adult (18-65) and elderly populations (≥65), with a 
diagnosis of Major Depressive Disorder (MDD), Bipolar Affective Disorder, Seasonal 
Affective Disorder, Dysthymia, or Postnatal (/postpartum) depression (as defined by DSM-V 
or ICD-10, or previous versions of these diagnostic manuals) were included.  
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Intervention. Randomised controlled trials (RCTs) and open label trials evaluating the effect 
of bupropion (any dose or formulation) on depressive symptoms were included.  
Comparator intervention. RCTS with a placebo-arm, head-to-head trials with no placebo-arm 
and augmentation trials were deemed eligible for review.  
Outcomes. Only studies evaluating effectiveness through validated measures were included, 
namely the following: Hamilton Depression Rating Scale (HDRS/HAM-D: (Hamilton, 1960); 
Montgomery Asberg Depression Rating Scale (MADRS: (Montgomery & Asberg, 1979); 
Inventory for Depressive Symptomology (IDS: (Rush et al., 1986); Structured Interview Guide 
for the Hamilton Depression Rating Scale — Seasonal Affective Disorder Version (SIGH—
SAD: (Williams, Link, Rosenthal, & Terman, 1988). 
Study Design. Only journal articles post 1990 were included for review, with case studies (≤ 
3 participants), expert opinions, and poster presentations excluded.   
Study Selection. 14372 reports were initially identified (see Figure 1); after adjusting for 
duplicates (9817), 4555 articles remained. 4417 articles were excluded as unsuitable based 
on title and abstract. 138 full text articles were evaluated, 87 of which were excluded for 
being: conference abstracts or presentations, pre-1990 trials, case studies, a non-included 
patient population, failure to separate results according to treatment or disorder, and for 
not containing original data. 51 studies ultimately met the criteria for qualitative synthesis, 
dividing into four major groups: those evaluating bupropion as a sole pharmacological 
intervention in MDD (n=27); those evaluating its co-prescribing with a second 
antidepressant in MDD (n=13); the treatment of ‘other’ populations such as bipolar 
depression and the elderly (n=11); and primary evaluation of side effects (n=13).  
 
Data Extraction. Data was extracted by two authors (KP and SA). Extracted data concerning 
patient characteristics and study results are available in Tables 1 and 2. For quantitative 
analysis, effect sizes were converted to Hedge’s g, to decrease the risk of bias associated 
with standardized mean differences. 
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Data Analysis. In light of the limited amount of data for quantitative analysis as well as the 
hypothesis that true effect sizes would differ depending on sample and treatment 
characteristics, random-effects models were chosen as most appropriate for the meta-
analysis. Statistical procedures were carried out using Stata 45, using the metan package for 
the meta-analysis, and the metafunnel and metabias packages for assessment of publication 
bias. P-values below 0.05 were accepted as being statistically significant. 
 
Results 
A) Bupropion monotherapy 
27 trials evaluating bupropion in the treatment of MDD were identified, running from 6- to 
44- weeks in treatment duration. Of these, 21 trials were double blinded RCTs, of which one 
had a two phase design (double blinded RCT, followed by open label phase), one was single 
blinded, and five were open label. Eleven studies compared bupropion with placebo; ten 
compared to an SSRI (of which five additionally had a placebo arm); four compared to an 
SNRI (of which two had a placebo arm); and one trial compared bupropion to an SARI, and 
one to a tricyclic antidepressant (TCA), of which neither had a placebo control. Bupropion 
was efficacious in reducing depression scores in 24 of the 27 trials, and, where evaluated, 
showed comparable levels of efficacy to the other classes of antidepressant.   
 
Placebo Trials  
Five of the six open-label placebo trials reported a statistically significant clinical 
improvement in favour of bupropion (Brown, Vornik, Khan, & Rush, 2007; Fava et al., 2003; 
Ferguson et al., 1994; Gross, Nourse, Wasser, & Bukenya, 2007; Walker et al., 1993), one 
(Tomarken, Dichter, Freid, Addington, & Shelton, 2004) did not demonstrate between group 
differences: they are described in Table 2. Of the six double blinded, placebo controlled 
RCTs, two evaluated flexible dosing of bupropion. In the earlier study (Lineberry et al., 1990) 
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(n=216) bupropion was titrated to a maximum of 100mg/TID. Intention to treat (ITT) 
analysis demonstrated significantly greater HAM-D, MADRS, and CGI changes for the 
bupropion group over six weeks in both observed case analysis (p<0.05 for all) and in last-
observation-carried-forward (LOCF) analysis (p<0.01 for all). 54% attained response (≥ 50% 
reduction in HAMD-D total scores) on bupropion, significantly more (p=0.01) than the 34% 
in the placebo group. In the work by Jefferson et al. (2006) (n=270) the majority of patients 
(59%) received maximum dosage (450mg/d) bupropion (vs 38% on 300mg/d). Clinician 
reported response rates (IDS-C-30) were statistically significant for the bupropion group 
(50% vs. 35%, p=0.009), but self-reported response rates were not (53% vs. 45%, p=0.084) at 
the 8 week endpoint; remission rates were significantly greater in both clinician (41% vs 27% 
respectively, p=0.01) and self-reports (32% vs. 18% respectively, p=0.005). 
Two RCTs evaluated fixed dosing regimens over eight-week timeframes, with contrasting 
results. In the most recent study (Koshino, Bahk, Sakai, & Kobayashi, 2013) ITT analysis of 
564 Japanese and Korean participants (randomised to bupropion 150mg/d, 300mg/d, and 
placebo in a 1:1:1 ratio) reported no statistical differences between bupropion SR and 
placebo on MADRS total scores (p=0.853), response (≥ 50% reduction in MADRS) or 
remission (MADRS ≤11) rates, though the authors note the significant changes in their 
placebo group by the study end that reduced between-group differences. Posthoc analysis 
showed a trend towards response in those diagnosed with severe MDD. The study had 
notably stringent inclusion criteria to reduce the potential enrollment of patients with mild 
depression, a factor reported to impact placebo response rates in clinical trials (Posternak, 
Zimmerman, Keitner, & Miller, 2002). However, mean MADRs baseline scores (31.8-32.1) 
did not seem to differ widely with those reported by other authors in this review who used 
the same measure. Conversely an earlier study of similar design (n=362), Reimherr, 
Cunningham, Batey, Johnston, & Ascher (1998) reported that bupropion dosed at 150mg/d 
and 300mg/d significantly reduced HAM-D and CGI-I total scores (p<0.05 and p<0.01, 
respectively) compared with placebo. Notably, this study had a lower study completion rate 
(54%) and, interestingly, of the 46% of patients that had prematurely discontinued, the 
majority were from the placebo group, with withdrawal due to inadequate response or 
because their condition had deteriorated.  
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A two phase trial evaluated the long-term efficacy and weight change (described later) of 
fixed dose (300mg/d) bupropion. Weihs et al. (2002) administered bupropion dosed at 150-
300mg/d in an open label design for eight weeks (phase 1); those who responded were then 
recruited for a 44 week double blind, placebo controlled randomised fixed dose (300mg/d) 
study (phase 2). In this study the primary outcome measure was time to relapse, defined as 
the prescription of new antidepressant or the use of electroconvulsive therapy (ECT), and 
the study did not report additional data on changes in HAM-D scores. In phase 2 (n=417) of 
those patients who relapsed, mean HAM-D scores were 21 (SD=4.4, 11-30) and a statistically 
significant difference in favour of bupropion over placebo was demonstrated when 
comparing the survival curves for the two treatment groups (p=0.004). In the placebo 
treatment group median time to relapse was 24 weeks after randomisation compared to 44 
weeks for the bupropion treatment group. Furthermore, survival estimates demonstrated 
that 52% of the placebo group would become depressed by the end of the study compared 
to 37% of the bupropion treatment group (p=0.004) and that by end of year 1 the odds of 
placebo group requiring treatment were 1.83 times greater than for those in the bupropion 
treatment group.  
In an inverse two phase design with a much smaller sample (n=16) Tomarken et al. (2004) 
administered bupropion dosed at 100-300mg/d in an double blinded, placebo controlled 
randomised design for six weeks (phase 1); at study end point participants from the 
bupropion group were titrated up to 400mg/d and participants from the placebo group to 
300mg/d of medication, in an open label design (phase 2) for a further six weeks. The 
primary aim of this study was evaluating efficacy of bupropion on specific symptom 
dimensions of depression (which are discussed later), however, the authors also 
administered the HAM-D. Both bupropion and placebo demonstrated linear declines on the 
HAM-D during phase one (p<0.001), though the rate of change was greater for bupropion 
than placebo (p=0.04). Although declines in mean scores were replicated in phase 2 
(p=0.005), no significant differences were observed between groups (p>0.3). 
In summary, bupropion demonstrated efficacy compared to placebo in five out of the six 
RCTs, and all but one of the open label trials, with one of the two fixed dosing studies 
showing no difference. Study sizes in the RCTs were generally reasonable, with the 
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exception of the Tomarken et al. (2004) cohort; follow-up periods were generally relatively 
brief, but consistent with typical antidepressant trials.  
A subset of 5 studies reported sufficient data to allow for quantitative analysis using meta-
analysis. Meta-analysis for the main effect of bupropion on depression scores as to 
compared to placebo control showed a consistent large effect favouring bupropion (Hedge’s 
g = 2.02, df = 4, p < 0.001, 95%-CI = 2.93 - 1.11; Figure 2). However, this analysis also 
revealed high heterogeneity of study findings (p = 0.001, I2 = 79.4%, τ2 = 0.832), which is 
reflected in a large prediction interval (PI = 5.28 - -1.24).  Moreover, both Egger’s (p = 0.043) 
and Begg’s (p = 0.027) tests for publication bias produced significant results. Thus, the 
strength of evidence produced by the present meta-analysis needs to be considered with 
extreme caution. 
 
Bupropion vs SSRI 
Ten RCTs identified evaluated the efficacy of bupropion against an SSRI: one compared with 
escitalopram (Clayton et al., 2006), five with sertraline (Coleman et al., 1999; Croft et al., 
1999; Kavoussi, Segraves, Hughes, Ascher, & Johnston, 1997; Rush et al., 2001; Rush et al., 
2006), two with fluoxetine (Coleman et al., 2001; Feighner et al., 1991) and two with 
paroxetine (Grunebaum et al., 2012; Kennedy et al., 2006) Nine trials employed a double 
blinded, randomised designs: six of which utilised a double dummy approach, which is a 
technique for retaining blinding when the two drugs cannot be made to appear identical; all 
participants thus take two treatments, one of which (depending upon the arm they are in) 
would be a placebo; and five also had a placebo arm. Trials varied in length from eight to 24 
weeks, and number of participants from 74 to 785.  
 
Bupropion vs. Escitalopram 
A large (n=785) RCT by Clayton et al (2006) randomised participants to receive bupropion XL 
(300-450mg/d, n=276), escitalopram (10-20mg/d, n=281) or placebo (n=273). A primary 
measure, reported later, was sexual functioning, but compared with placebo both drugs had 
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statistically superior response (p=0.015 and p<0.001, respectively) and remission rates 
(p=0.018 and p<0.005, respectively), as measured by the HAM-D, with no difference 
between the treatment groups. However, separation from placebo was not achieved at the 
statistical level of 0.05 for bupropion for mean HAM-D total scores in the individual or 
pooled analysis. This is surprising given a statistically significant response rate was achieved 
in the pooled analysis for bupropion. The authors attribute this discrepancy to their sample 
size and large placebo response (53%).   
 
Bupropion vs. Sertraline  
Five studies compared bupropion and sertraline, two with placebo arms (Coleman et al., 
1999; Croft et al., 1999). Three employed a double blinded, double dummy design (Coleman 
et al., 1999; Croft et al., 1999; Kavoussi et al., 1997), one a double blinded design (Rush et 
al., 2001) and one was not blinded (Rush et al., 2006). Trials ranged from eight to 16 weeks 
and 248 to 583 patients. The most recent RCT (Rush et al., 2001), which is fourteen years 
old, employed a double blind, randomised parallel design in 248 over a 16 week treatment 
phase. Mean HAM-D scores reduced for both treatment groups, with high response 
(bupropion, 66% and sertraline, 74%) and remission (bupropion, 55% and sertraline, 63%) 
rates reported, with no between-group differences. Interestingly a larger (n=583) open 
label, similar mean dosage, trial by the same group (Rush et al., 2006) recorded significantly 
lower response rates; however there was a broader inclusion of patients with other 
comorbid somatic or psychiatric disorders, and it is not clear to what degree these factors 
might have altered the results. Findings from the RCT are in accord with the earlier, similarly 
designed (n=241) trial by Kavoussi et al (1997). Both groups demonstrated a ≥50% 
improvement in HAM-D scores from week six to study endpoint (week 16), with no 
statistical between-group difference on the HAM-D, CGI-S or CGI-I. Both groups also 
demonstrated ≥50% study-end improvement in anxiety scores, as measured by the HAM-A. 
Neither trial had a placebo arm, nor were p values reported. 
Two early studies employed more rigorous, and similar, methodological designs. Coleman et 
al. (1999) reported mean HAM-D scores in the bupropion, sertraline and placebo groups 
improved by ≥50% by week 8, but only bupropion was statistically significantly superior to 
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placebo by this point (p<0.05). Croft et al (1999) reported the same reduction in depression 
scores by week 8 (from week 6) (p<0.05) LOCF analysis for both active treatment groups, 
with no statistically significant between them. A statistically significant HAM-D clinical 
response was observed in bupropion (66%, p<0.004) and sertraline groups (68%, p=0.002) 
compared to placebo (47%). These two trials, plus work by Reimherr et al (1998) reported 
that individuals on bupropion showed significantly greater improvement on CGI-S and CGI-I 
scores. In the Coleman et al (1999) study no difference between sertraline and placebo was 
established at any time for the CGI-S or CGI-I. Croft et al (1999) reported that although no 
statistical difference between the groups was observed both treatments were statistically 
superior to placebo in CGI-S (bupropion, p=0.005 and sertraline, p=0.05) and CGI-I scores 
(p<0.01).  
In summary, all trials that included a placebo arm reported bupropion as being significantly 
superior to placebo. In the majority of the studies, bupropion and sertraline demonstrated 
comparable efficacy, with the exception of Coleman et al (1999) cohort where bupropion 
but not sertraline was superior to placebo.  
 
Bupropion vs Fluoxetine 
Two RCTs evaluated bupropion and fluoxetine, with similar study designs including placebo 
arms. The most recent trial was in 2001 (Coleman et al., 2001); over the 8 week intervention 
mean HAM-D scores decreased across all groups (total n=427). No statistical difference in 
response rates was observed between bupropion (56%), fluoxetine (57%) and placebo 
(50%); however for remission (47%, 40%, 32% respectively), a statistically significant greater 
rate was seen for bupropion, but not fluoxetine, over placebo (p<0.05). The earlier trial 
(Feighner et al., 1991) had a smaller sample (n= 119) and shorter treatment phase (6 
weeks); data similarly demonstrated no statistical difference in HAM-D, CGI-S or CGI-I 
scores, or response rates (bupropion, 62.5% and fluoxetine, 58.3%), with no statistical 
difference demonstrated between treatment groups.  
 
Bupropion vs. Paroxetine 
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Two RCTs compared the efficacy of bupropion with paroxetine, neither utilising a placebo 
arm. Grunebaum et al (2012) utilised an initial eight week treatment phase (bupropion 
n=38, paroxetine n=36) in individuals with MDD and elevated suicidal risk factors, followed 
by a 16 week continuation phase design for those patients who had initially responded to 
treatment. The primary outcome was suicidal behaviour and ideation, measured on a 
modified HDRS scores (mHDRS, subtracting suicide item). A reduction in mHDRS scores was 
reported for both active treatment groups; however for each point more severe at mHDRS 
baseline, symptoms were 0.46 points lower with paroxetine by week eight. These data 
suggests that patients with more severe global depression symptoms (minus suicidality) 
improved modestly more with paroxetine when controlling for suicidal ideation index at 
baseline. The earlier trial by Kennedy et al (2006) had a larger sample (n=131) and lower 
mean dosage of medication for both drugs, and reported a statistically significant reduction 
in HDRS scores for both treatment groups (p<0.01), with no significant differences between 
bupropion and paroxetine on the HDRS scores, response or remission rates. Overall the lack 
of a placebo arm hinders the ability to determine either drug’s absolute efficacy, though 
they produced comparable effects in terms of reduction in mean HDRS scores for both 
treatment groups, with the latest study showing a particular advantage for paroxetine in 
suicidal patients.   
 
Bupropion vs. SNRIs 
Four trials evaluated bupropion and a Selective Norepinephrine Reuptake Inhibitor (SNRI), 
three of which looked at venlafaxine (Hewett et al., 2009; Hewett, Gee, et al., 2010; Thase 
et al., 2006) and one duloxetine (Rosso, Rigardetto, Bogetto, & Maina, 2012). The 
venlafaxine trials were all double blinded, double dummy designs, and two contained a 
placebo arm; sample size varied from 324–569 subjects and treatment phase from eight to 
12 weeks. The single trial evaluating bupropion and duloxetine had a small sample (n=46) 
and short treatment duration (6 weeks), (Rosso et al., 2012).  
 
Bupropion vs. Venlafaxine 
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The trial by Hewett et al (n=384) (Hewett et al., 2009) reported a statistically significant 
difference in mean MADRS total scores for bupropion and venlafaxine compared to the 
placebo in the LOCF (p=0.006 and p=0.001, respectively) and observed case analyses 
(p=0.003 and P<0.001, respectively), as well as on CGI-I (p<0.001 and p=0.009), CGI-S 
(p=0.003 and p<0.001), and HAM-A (p=0.019 and p<0.001). A statistically significant greater 
proportion of bupropion and venlafaxine patients, compared to placebo, met the criteria for 
response (p=0.033 and p<0.001, respectively) and remission (p=0.004 and p<0.001, 
respectively) at week 8, with no significant differences between the two active treatment 
groups. 
However a larger (n=390) subsequent trial by the same group (Hewett, Gee, et al., 2010) 
reported no statistical significance in the least squares mean change from baseline MADRS 
scores, at study endpoint (week 8) for bupropion (180mg/d) compared to placebo. Given 
the limitations of the studies analysis protocol, no further comparisons at the 0.05 level 
between active treatment groups and placebo were deemed appropriate, and further 
results are therefore purely descriptive. Comparison of patients classified as responders or 
remitters (according to MADRS and CGI-I criteria) were significant for Venlafaxine (p<0.05) 
but not bupropion, and this was also the case for CGI-S and HAM-A scores (p<0.01, 
venlafaxine). In this latter study, Hewett, Gee, et al (2010) argued that the study enrolled a 
population that was inherently less responsive to bupropion - and more so to venlafaxine - 
although they recognized that such an argument was speculative.  
Thase et al (2006) conducted a randomised, double blind, non-placebo controlled study 
comparing bupropion and venlafaxine in 324 outpatients with MDD, and reported similar 
response and remission rates for the bupropion and venlafaxine treatment groups. Although 
the study reported that a significant difference in favour of bupropion was observed in the 
LOCF analysis for percentage of patients categorised under remission (for both HAM-D and 
CGI-I criteria), no p values were provided to further interpret this, and antidepressant 
efficacy was a secondary aim of the study. In summary bupropion up to doses of 450mg and 
venlafaxine up to 225mg showed comparable levels of antidepressant activity in two trials. 
One trial indicated superiority of venlafaxine over bupropion and placebo, however results 
should be interpreted as descriptive. In some studies mean severity scores were trending 
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downward at the end of treatment, suggesting there was potential for patients to achieve 
remission if treatment phases were extended.   
 
Bupropion vs. Duloxetine 
One study evaluated the efficacy of bupropion (300mg/d) vs. duloxetine (120mg/d) in a 
small scale (n=46) six week single blinded, randomised trial in individuals with MDD resistant 
to SSRIs (Rosso et al., 2012). Rosso et al. reported that both groups demonstrated a 
statistically significant reduction in mean HAM-D and CGI-S scores at study endpoint 
(p<0.001), however no differences between treatment groups were found at any time point. 
Although a similar percentage of patients were categorised as responders (60-70%) and 
remitters (30-40%), there were no statistical differences between the treatment groups or 
from baseline to study endpoint (week 6). Whilst the results are positive, given the sample’s 
refractory cohort, and support class change in MDD refractory to SSRIS, interpretation is 
hindered by the lack of a placebo arm and the small sample size. 
 
Bupropion vs. Trazadone 
One study, a RCT, evaluated the relative efficacy of bupropion (225-450mg/d) and trazadone 
(150-400mg/d), a serotonin antagonist and reuptake inhibitor (SARI) (Weisler et al., 1994). 
After a one week placebo lead in, 124 outpatients with mild-moderate depression were 
randomised to one of the two drugs. At the six week follow-up there were no significant 
differences between the compounds, though trazadone showed earlier gains that might 
have been due to improved sleep. 58% of bupropion and 46% of trazadone patients were 
rated as much or very much improved by the end, though the study lacked a placebo arm, 
and only numerical values of improvement were provided.  
 
Bupropion vs. TCAs 
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A double blind, double dummy RCT (Masco et al., 1994) evaluated bupropion (n=55) against 
nortriptyline (n=50) over a six week treatment phase. Improvements on HAM-D scores and 
response rate (bupropion, 40% vs. nortriptyline, 48%) were comparable across the two 
treatment groups. As with the trazadone study, there were some early benefits for 
nortriptyline that the authors considered might be due to a disproportionate weighting of 
the sleep index on the HAM-D.  
 
 
B) Bupropion combined with other medication 
Thirteen reports evaluated bupropion co-prescribing, with sample sizes from 25 to 565 
participants, and trial durations of 4 to 52 weeks: five were RCTs, of which four were 
double-blinded; seven were open label studies and one was a longitudinal study. Two were 
part of the STAR*D trial, of which one was a double blinded, randomised trial (Bech, Fava, 
Trivedi, Wisniewski, & Rush, 2012) and one an open label, randomised trial (Trivedi, Fava, et 
al., 2006). 
 
Bupropion co-prescribed with SSRIs 
Five reports evaluated the efficacy of adding bupropion to SSRIs. A methodologically unique 
work by Weissman et al (2015) followed the progress of mothers with depression (n=76) 
randomised to receive bupropion, escitalopram, or their combination over 12 weeks; their 
children’s (n=135) wellbeing was independently assessed. There were no between-group 
differences for the women, all groups showing statistically significant improvements as 
measured on the HAM-D (p<0.001); there was an overall remission rate of 67%. However 
the effect upon their children varied, and depended upon the mothers’ baseline symptom 
profiles; mean Children’s Depression Inventory (CDI) scores declined signiﬁcantly among 
children whose mothers received escitalopram monotherapy compared with both 
bupropion monotherapy (p<0.04) and combination treatment of bupropion and 
escitalopram (p<0.001). Subanalysis of this interesting finding showed that those children 
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with mothers with a so-called high ‘negative affectivity’ (which includes the symptoms of 
guilt, irritability, and fear/anxiety) only improved when their mothers were on escitalopram; 
mothers in this group reported improvements in their abilities to listen to their children, and 
the children described the mothers as becoming more caring during treatment. Negative 
affectivity has been linked with serotonergic dysfunction, which may explain bupropion’s 
lack of impact on this domain.  
A single blind RCT (Gulrez, Badyal, Deswal, & Sharma, 2012) evaluated 60 outpatients 
showing a partial response on SSRIs (escitalopram 10-30mg/day, citalopram 20-60mg/day, 
paroxetine 25-75mg/day, and sertraline 50-200mg/day; all on treatment 4 weeks). 
Participants were randomly assigned to have either placebo or bupropion sustained release 
(150-300mg) added to their antidepressant. By the end of week 4, both groups had 
significantly improved, but the decrease in depression scores (measured on the HDRS, 
MADRS and ADI) were significantly greater in those co-prescribed bupropion.   
Three open label studies evaluated the addition of bupropion to citalopram or escitalopram, 
an SSRI that is highly selective for the serotonin reuptake transporter. A novel design 
naturalistic study by Lam, Hossie, Solomons, & Yatham (2004) explored treatment strategies 
– whether to augment or switch medication - in 61 individuals taking either citalopram or 
bupropion SR (at a therapeutic dose but showing minimal improvement) for at least six 
weeks. Eligible participants, all of whom had failed to respond to at least one previous 
antidepressant, had, in alternate months, the other medication added to their treatment, or 
were switched to the other drug. An advantage of such a methodology is that it attempts to 
address the issue of whether it is the combination of medications (which could be additive 
or synergistic) or the novel compound that accounts for any improvement. At six weeks 
treatment, the combination condition (n=32) was superior to a monotherapy switch (n=29) 
in terms of clinical change on the SIGH-SAD score (p<0.04) and the proportion of 
participants in remission (28% vs 7%, p<0.05). The combination remission rate was low, but 
with the caveat that it was measured at six weeks’ treatment. Leuchter et al. (2008) 
examined the co-prescribing of citalopram (mean dose 18mg/day) and bupropion sustained 
release (mean dose 329mg/d) over twelve weeks in 51 medication free outpatients with 
chronic or recurrent MDD. Participants were commenced on escitalopram 10mg/d, with 
bupropion sustained release 150mg/d added at week 1; they were eligible for an increase in 
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either medication by week 4 (and for bupropion also at weeks 6-10) if they failed to show 
any, or suboptimal, improvement; mean doses by the trial end were 18mg/d and 329mg/d 
respectively. 62% showed a response to treatment, 50% attained remission (QIDS-C16≤5). 
Rates of discontinuation due to side effects were low, at 6%. Similarly, Mohann, Eller, Vasar, 
& Nutt (2009) prescribed 10-20mg/d of escitalopram to 135 participants with MDD in a 12 
week trial (those showing 50% decrease in MADRS scores at week 4 being put on the 
higher dose); non-responders at week 12 were then co-prescribed 150-300mg/d (depending 
upon response) bupropion for an additional 6 weeks. By the end of twelve weeks 60.7% 
were responders, 58.5% remitters on citalopram monotherapy; 41 participants –defined as 
non-responders - entered the co-prescribing phase, and 61.0% attained response, 53.7% 
remission in the 6 week follow-on. Interestingly, sub-analysis of symptom changes showed 
that melancholic features of depression were less responsive to escitalopram monotherapy, 
but that these appeared to respond well to bupropion augmentation. 
Overall, with regards to adding bupropion to SSRIs, there was only one double-blinded RCT, 
though this did not have a placebo group, and was in a specific cohort of depressed 
mothers. In this study bupropion and bupropion co-prescribing showed results comparable 
– though not superior to – SSRI prescribing; the data are interesting in terms of the 
differential outcomes in the children. The data from the single blinded RCT and open label 
trials support superior efficacy of bupropion, though the sample sizes are modest, and 
methodologically, open label trials, with their lack of placebo, are open to challenge.  
 
Bupropion co-prescribed with non-SSRIs 
 Two studies compared the efficacy of bupropion in adjunction with a non-SSRI 
antidepressant, in both instances a SNRI. 
A six-week double blind placebo-controlled RCT (Fornaro et al., 2014) evaluated bupropion 
SR (150 or 300mg/day) or placebo added to duloxetine (60-120mg/day) in 48 outpatients 
with MDD (all of whom had failed at least one drug trial) with DSM-IV criteria atypical 
features (which include increased appetite and food consumption, weight gain, 
hypersomnia and atypical diurnal variation in mood). No statistically significant differences 
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were seen between groups, with measurements including the Structured Interview Guide 
for the HAM-D with Atypical Depression Supplement (SIGH-ADS) in addition to the GAF and 
HAM-D; 26.1% (duloxetine) and 21.7% (placebo) response rates were attained. The authors 
noted that the presence of a higher number of atypical features, which generally occur in up 
to a fifth of those with MDD, significantly predicted non-response, as has been 
demonstrated in other studies, and may have affected their outcomes.   
Spier (1998) evaluated the use of adding bupropion to patients with MDD in a private 
practice clinic already on venlafaxine or an SSRI in an open-label trial assessing symptom 
relief and management of drug-induced side-effects in monotherapy non-responders 
(n=15), and responders (n=10) with side-effects, respectively. A numerical reduction in 
average CGI scores was observed after response to second agent had stabilised, scores 
reducing from 5.2 (4–7) to 2.2 (1–4). 12 of the 15 monotherapy non-responders showed a 
response after the addition of bupropion, but only two of the 10 prescribed this to manage 
medication side-effects showed any amelioration of their problems. The small sample size, 
and a very heterogeneous population, inevitably means these results should be treated with 
caution. 
 
Bupropion as part of multiple medication trials 
Six studies compared the efficacy of Bupropion in multiple medication trials. 
As part of the highly influential STAR*D project, Trivedi et al (2006) randomised (but in an 
unblinded fashion) 851 individuals with MDD not remitting on citalopram (mean dose 
55mg/d, mean duration 11.9 weeks) to additionally receive either bupropion XL (n=565, 
dose up to 400mg/d) or buspirone (n=286, dose of up to 60mg/d); there was no placebo 
arm. Both treatments had similar results on the HRSD-17 remission, QIDS-SR-16 remission, 
and QIDS-SR-16 response; however bupropion had a greater reduction (p<0.04) and overall 
score (p<0.02) in QIDS-SR-16 scores, and a lower side-effect drop-out rate (p<0.009) by the 
12-week study end. Subsequent analysis by the same group (Bech et al., 2012) focused on 
what the authors termed the ‘pharmacopsychometric triangle’ in comparing bupropion with 
buspirone augmentation. Under this model, which composites the domains of 
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antidepressive activity, side-effects, and quality of life, bupropion was superior in all 
domains (though not to statistical significance for ‘quality of life’). 
In a double blind RCT Blier et al (2010) randomised 105 medication-free participants with 
MDD to receive either fluoxetine monotherapy (n=28, dose 20mg/d), or one of three 
mirtazapine (30mg/d) combination groups: with fluoxetine (20mg/d, n=25); with venlafaxine 
(225mg/d, n=26); or with bupropion (150mg/d, n=26) over a six week period. Although, 
similarly to the STAR*D work, there was no placebo group, the monotherapy group allowed 
for evaluation of the hypothesis that any response or remission might be solely due to 
having more time on an initial compound. There were no significant differences in inter-
group drop-out rates, suggesting that polytherapy was tolerated well, but all the 
combination groups showed significantly greater HAM-D improvements than fluoxetine 
monotherapy, producing a number needed to treat (NNT) of 3 to 5 over monotherapy. 
However the combination protocols did not result in any greater rapidity of response. There 
were no significant between-combination-group differences on the MADRS or CGI. 
Discontinuation of any drug in those who had shown a marked response led to a relapse in 
approximately 40%.  
A post-hoc analysis of data from a subgroup of patients enrolled in a large (n=296) 52 week 
open label multi-centre study (Clayton et al., 2014) evaluated the addition of aripiprazole to 
either bupropion (n=47) or SSRIs/SNRIs (n=245, data pooled) in individuals with MDD. The 
primary outcome measurements were the safety and tolerability of these combinations, 
which are reported elsewhere in this paper. For both groups, LOCF improvements occurred 
over the course of the one year trial; mean changes of -1.4 points in CGI-S scores occurred in 
the bupropion group and -1.5 points in the SSRI/SNRI group (observed case n=76). In a six 
week prospective open label study, DeBattista, Solvason, Poirier, Kendrick, & Schatzberg 
(2003) examined the efficacy of bupropion XL (150 or 300mg/day) added to 25 participants’ 
existing antidepressants (all with MDD and an inadequate response on their current 
treatment of ≥4 weeks), which included SSRIs (fluoxetine, paroxetine, and sertraline) and 
the SNRI venlafaxine. A statistically significant reduction in HDRS symptoms was 
demonstrated by the trial end (p<0.001), with 54% demonstrated a clinical response of 
≥50% symptom reduction. No between drug differences were noted, though the sample size 
was very small. Bares et al (2013) compared the efficacy of antidepressant monotherapy 
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(ADM) with combinational anti-depressant (CAD) treatment in sixty inpatients with 
treatment resistant depression (TRD) in a randomised six week open label study. After a 
short initial washout period of a day or two, eligible participants were randomly allocated to 
either six week ADM or CAD groups, with responders from both entered into a further eight 
week follow-up protocol. The specific new treatment(s) was/were chosen by clinicians 
based upon professional judgement of individuals’ mental state and past psychiatric 
histories, excluding medications that had previously failed, or drugs of the same class (with 
the exception of SSRIs).  There were no differences from baseline between ADM and CAD 
groups as measured by change on MADRS or response rates; whilst bupropion was 
administered to participants in this study, the total number on this in both groups (and the 
combination(s) in the CAD group) are not recorded, nor are the other drugs reported.  
Interpreting these findings, the methodologically strongest work, by Trivedi et al (2006) and 
Blier et al (2010) support the addition of bupropion to a range of existing first-line 
antidepressants. However there is little to delineate treatment options further, and the lack 
of placebo arms is notable.   
 
C) Other population groups 
Older Adults 
Three studies evaluated the use of bupropion in older adults (≥65 years of age) with MDD. 
Two were RCTs, evaluating bupropion in comparison to placebo (Hewett, Chrzanowski, et 
al., 2010) and with paroxetine (Weihs et al., 2000). One naturalistic study investigated the 
use of both bupropion monotherapy and its combination with SSRIs (Steffens, Doraiswamy, 
& McQuoid, 2001). Trials ranged from 6-12 weeks with bupropion doses ranging from 100-
400mg/d. All three studies showed bupropion to be significantly efficacious.  
The most recent double-blind RCT, by Hewett, Chrzanowski, et al (2010) demonstrated 
efficacy for bupropion XR in comparison to placebo (p<0.05) over ten weeks in a large 
sample (n=418); from baseline the median changes in MADRS total score were -15.0 and -
11.0 for bupropion XR and placebo, respectively. Weihs et al (2000) (n=100) found 
significant efficacy for both bupropion SR (n=48) and paroxetine (n=52) for the treatment of 
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depression in a double-blinded, double-dummy RCT. Mean HAMD (LOCF) scores were 
similar at baseline for both treatment groups with a 59% reduction in total score for 
bupropion SR and a 63% reduction in total score for paroxetine by week 6. LOCF analyses 
found no significant difference in mean HAMD scores between the two drugs. Secondary 
analyses of CGI-S, CGI-I and HAM-A scores showed improvement in both treatment groups 
at week 6. No significant differences were found between treatment groups in mean CGI-S, 
CGI-I or HAM-A scores.  
In the naturalistic trial, Steffens et al (2001) (n=31) investigated the use of bupropion SR or 
IR monotherapy (n=15) and its combination with an SSRI (n=16), with prescribing based 
upon clinicians’ choices. For bupropion monotherapy, 61% were responders (MADRS<15), 
with 50% achieving partial (CGI=2) or complete (CGI=1) remission. Bupropion and SSRI 
combination therapy showed 81.2% response (MADRS<15) with 56.2% showing partial 
(CGI=2) or complete (CGI=1) remission. Overall, 74.2% were classed as responders (defined 
as a MADRS<15), with 53.3% achieving a partial (CGI=2) or complete (CGI=1) remission. 
The general dearth of research in elderly patient groups makes it difficult to draw firm 
conclusions. However, of the three included studies identified, all show significant efficacy 
for the use of bupropion in the treatment of MDD, though only one study was a RCT 
comparing with placebo, and the other works have notably fewer participants, meaning 
caution is required in interpretation. 
 
Bipolar Affective Disorder 
Although defined by pathological mood elevation, depression (so-called bipolar depression) 
constitutes the majority of illness burden (Lloyd, Giaroli, Taylor, & Tracy, 2011). Three 
studies investigated the use of bupropion in this group: one double-blind RCT compared it 
to the selective α2 adrenergic antagonist idazoxan (Grossman, Potter, Brown, & Maislin, 
1999), a single-blinded RCT compared with the anticonvulsant and mood stabiliser 
topiramate (McIntyre et al., 2002), and a mixed-design study compared bupropion to 
sertraline and venlafaxine in combination with mood stabilisers (Post et al., 2006).  Trial 
length varied from 6 to 8 weeks with bupropion doses ranging from 75-450mg/d. 
22 
 
In a small study of 14 individuals with bipolar depression, Grossman et al (1999) found 
significant reductions in HDRS total score by the end of the 6 week trial for both bupropion 
and idazoxan. (t=-3.51, df=6, p=0.01, for idazoxan; t=-3.30, df=8, p=0.01, for bupropion). In a 
slightly larger (n=36) and longer trial, McIntyre et al (2002) found significant improvements 
in HDRS-17 total score from baseline to endpoint for both bupropion SR and topiramate 
(p<0.001). Total mean HDRS-17 score decreased from 20 to 9.5 by endpoint for bupropion 
and from 20.5 to 10 by week 8 for topiramate. This was also reflected in CGI-I total scores, 
where a significant reduction was observed for both treatment groups at week 8 (p<0.005), 
with no significant differences between bupropion and topiramate (t(36)=1/653, p=0.092). 
The number of patients meeting predetermined criteria for response was significant for 
both bupropion SR (59%) and topiramate (56%) [t(17)=2.661, p=0.03 and t(17)=2.542, 
p=0.04, respectively], and no significant between group differences were observed 
[(t(36)=1.754, p=0.097].  
Post et al (2006) investigated the use of bupropion, sertraline and venlafaxine for bipolar 
depression as adjuncts to mood stabiliser treatment with a mixed design of open label 
(n=27) and masked randomisation (n=147). Continued medication included lithium (n=68), 
valproate (n=93), carbamazepine (n=16), lamotrigine (n=8), typical antipsychotics (n=8) and 
atypical antipsychotics (n=30). Response rates (≥50% improvement in IDS score) were 49% 
for bupropion, 53% for sertraline and 51% for venlafaxine by the study endpoint (week 10). 
Remission rates (IDS score <12) were 41%, 36% and 34% respectively. No significant 
differences were found between treatment groups.  
Collectively these studies suggest efficacy of bupropion in the treatment of bipolar 
depression, although no significant differences were observed between the active 
comparators. However, interpretation is once again restricted due to the dearth in research 
within this population and notable methodological issues including a small sample size and 
absence of a placebo group.   
 
Seasonal Affective Disorder 
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Three studies evaluated the use of bupropion in seasonal affective disorder (SAD). One 
prospective study utilised bupropion prophylactically in a double-blinded, randomised 
design (Modell et al., 2005), and two adopted open label designs (Dilsaver, Qamar, & Del 
Medico, 1992; Seo et al., 2013). Studies ranged from 5 to 8 weeks in length, with doses of 
bupropion ranging from 150-400mg/d.  
In their large (n=1042) multi-site RCT of individuals with a diagnosis of SAD but currently 
asymptomatic, Modell et al (2005) randomised participants to receive either bupropion or 
placebo, and found significant reduction in recurrence rates by the following Spring in the 
active group. Of the total sample, 16% of patients experienced a recurrence of major 
depression whilst on Bupropion XL, compared to 28% of patients in the placebo group, with 
an overall relative risk of 0.56. Bupropion XL was favoured over placebo across all three sites 
(χ2=3.03, df=1, p=.081; χ2=3.62, df=1, p=.057; and χ2=14.1, df=1, p=.001, respectively) 
supporting bupropion’s use in preventing recurrence of seasonal major depressive episodes.  
Both open-label trials demonstrated a significant reduction in depressive symptoms. The 
more recent work by Seo et al (2013) (n=52) found a significant reduction in SIGH-SAD total 
score by 53% from baseline (27.6± 6.5) to week 8. (12.2 ± 6.3) (p<0.001). The earlier, and 
considerably smaller (n=15) work by Dilsaver et al (1992) found a significant improvement 
on HAM-D total score from baseline (18.3±6.9) to study end (3.2±2.2) with an average 
reduction of 15.2 (SD±5.7; t=9.6, df = 12, p<.0001); there were also significant reductions of 
modified HAM-D (mHAM-D) total score from baseline (25.5±6.4) to treatment end (4.1±3.1) 
with an average reduction of 21.4 (SD±5.2; t=15.4, df=14, p<.0001).  
Although yet to be replicated, (Modell et al (2005) demonstrated the potential prophylactic 
potential of bupropion in patients with SAD. Open label trials have also demonstrated the 
efficacy of bupropion in reducing depressive symptomology. However, given the limited 
number of trials these findings should be considered preliminary. 
 
Dysthymic Disorder 
A single open-label study evaluated bupropion SR in the treatment of dysthymic disorder, in 
an 8 week trial of 21 patients (Hellerstein, Batchelder, Kreditor, & Fedak, 2001). A significant 
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improvement was shown across all measures of symptomatology (p< 0.001); HAM-D scores 
decreased by 73% from 21.71 (SD=5.57) at baseline to 5.90 (SD=3.60) at week 8 (p<.001). 
Cornell Dysthymia Rating Scale (CDRS) total scores also showed a significant decrease from 
baseline (36.33, SD=9.85) to week 8 (12.43, SD=7.90) (P<0.001). Although in support of 
bupropion in the treatment of dysthymia, methodologically sound replication is required to 
validate these preliminary positive findings. 
 
Postpartum depression 
One small (n=8) study evaluated bupropion SR in the treatment of postpartum depression in 
an 8 week trial of open-label design (Nonacs et al., 2005). Overall, patients showed a 
significant response to Bupropion treatment, with a significant reduction in HAMD, CGI and 
Kellner depression scores (p<0.005). A significant decrease was shown in HAMD scores by 
week 4 (p<0.05, Wilcoxon signed-ranks test). Given the small sample and study design, 
further validation of findings is required in support. 
 
D) Side effects 
Weight change 
Fourteen studies, involving 8137 participants (duration 6-52 weeks) reported bupropion-
related weight changes (see Table 3). Overall, the majority concurred that there was 
significant weight loss in bupropion treated patients (Coleman et al., 1999; Coleman et al., 
2001; Croft et al., 2002; Croft et al., 1999; Jefferson et al., 2006; Reimherr et al., 1998; 
Settle, Stahl, Batey, Johnston, & Ascher, 1999; Weihs et al., 2002), though some studies 
reported a small weight increase (Blier et al., 2010; Clayton et al., 2014) or no significant 
change (Hewett et al., 2009; Hewett, Gee, et al., 2010; Koshino et al., 2013; Thase et al., 
2006). 
Six double blinded RCTs reported significant weight loss during bupropion treatment, 
including two long-term (52 week) follow-up studies. In the work by Weihs et al (2002) – the 
antidepressant efficacy data are reported earlier in this review – there was an initial 8 week 
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open label phase of 518 participants with recurrent major depression treated with 
bupropion SR 300mg/day; following this the responders (n= 471) entered a 44 week double 
blind, placebo controlled phase where they were randomised to continue bupropion or to 
switch to placebo. At week 52, no fluctuations in weight were found in the placebo group 
compared with baseline (+0.18kg; SD = 11.0), whereas the bupropion SR group had a mean 
weight loss of 1.13 kg (SD = 15.8); as noted earlier the bupropion cohort had significant 
improvements in mood over placebo, and one might otherwise expect more illness-driven 
weight loss in the more depressed placebo group. Interestingly, one bupropion treated 
patient discontinued from the study due to weight loss of approximately 7.8 kg or 15.2% of 
her baseline body weight. In a similarly designed open-label study, Croft et al (2002) 
reported at a mean 1.4 kg loss by week 8 in the open-label phase; following double-blind 
randomisation at that point, mean weight changes of -1.15kg were reported for the 
bupropion group (N=2101) and +0.02kg for the placebo arm (N=213) by week 52.  
Five briefer 8-week, multicentre, randomised, double-blind, double-dummy placebo 
controlled studies (totaling 2957 subjects with MDD), also reported weight decreases with 
bupropion (Coleman et al., 1999; Coleman et al., 2001; Croft et al., 1999; Reimherr et al., 
1998; Settle et al., 1999) across these trials median weight loss ranged from 0.9kg to 1.49kg, 
compared with losses of 0.5kg on sertraline and 1.49kg fluoxetine, and weight gain of 0.1-
0.2kg in a placebo groups. In the studies by Reimherr et al (1998) and Settle et al (1999), 
weight loss was dose dependent, with larger mean decreases on higher dosing regimens.  
Four double-blind RCTs reported minimal weight changes over 8 to 12 weeks of bupropion 
treatment (n=2070), though only the work by Koshino et al (2013) reported statistical 
comparisons; they found no significant differences in weight change in a cohort of 569 
depressed Asian subjects treated with bupropion 150mg/d, 300mg/d or placebo. Thase et al 
(2006) found a mean weight decrease in the bupropion XL group of 0.1 kg compared with a 
gain of 0.1kg in the venlafaxine XR group. Hewett et al (2009) and Hewett, Gee, et al (2010) 
described minimal 8-week weight changes for bupropion, venlafaxine, and placebo groups.  
Two studies (n=358) reported mean weight gains associated with bupropion treatment, 
though these were studies where it was co-administered with another antidepressant. Blier 
et al (2010) (n=66) reported significant mean weight increases in the bupropion plus 
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mirtazapine (M=2.7 kg, SD=2.4), venlafaxine plus mirtazapine (M=2.2 kg, SD=2.5) and 
fluoxetine plus mirtazapine groups (M=3.1 kg, SD=2.5) as compared to fluoxetine 
monotherapy (p < 0.001). In a 52-week open label study (n= 292) by Clayton et al (2014) 
found mean weight gains of +3.1 kg for bupropion plus aripiprazole, and +2.4 kg for an 
SSRI/SNRI plus aripiprazole.  
 
Sexual functioning 
Eleven studies (total participant n=5582) measured effect of bupropion on sexual 
functioning in patients with MDD (see Table 3). The majority divided sexual dysfunction into 
sexual desire disorder, sexual arousal disorder and orgasm dysfunction, while one study 
reported sexual functioning as using a single measure. The consensus across the literature 
was that bupropion did not differ significantly from placebo in causing sexual dysfunction; 
whilst it improved sexual functioning in patients experiencing SSRI-induced sexual 
dysfunction.  
Regarding causing sexual dysfunction, Croft et al (1999) and Coleman et al (1999) both 
reported that significantly more patients treated with sertraline experienced orgasmic 
dysfunction than subjects treated with bupropion SR or placebo, with an onset of orgasm 
dysfunction occurred as early as day seven in up to a sixth of those on sertraline. Following a 
16 week randomized clinical trial (N= 248), Segraves et al (2000) reported that compared to 
bupropion, more patients in the sertraline group experienced sexual desire disorder (63% of 
men and 41% of women) and sexual arousal disorder (19% in men, p=0.02; 12% in women, 
p=0.05); bupropion treatment was related with an increase in sexual satisfaction (from 57% 
to 79%). Clayton et al (2006) combined data from two double-blind, placebo-controlled RCTs 
comparing bupropion (N=276) to escitalopram (N=281) on measures of sexual functioning. 
They found, in both the individual studies and the pooled dataset, the incidence of orgasm 
dysfunction and the incidence of worsened sexual functioning at the end of the treatment 
(week 8) were statistically significantly lower with bupropion and placebo than with 
escitalopram (p<0.05), and not statistically different between bupropion and placebo. 
Similarly, Hewett et al (2010) reported no significant difference between bupropion patients 
and placebo on the Changes in Sexual Functioning Questionnaire (CSFQ), while venlafaxine 
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treated subjects experienced significant decreases on arousal and orgasm subscales 
(p<0.05) in an 8 week double-blind, placebo-controlled RCT (N=591). A double blind, double 
dummy RCT (Coleman et al., 2001) compared bupropion to fluoxetine. The overall incidence 
of sexual desire disorder significantly decreased only in the bupropion group by the week 8 
endpoint (p<0.05). Sexual arousal disorder occurred in significantly more fluoxetine than 
bupropion or placebo treated patients (p<0.05), with no difference between bupropion and 
placebo at any point. The incidence of orgasm dysfunction in those on fluoxetine 20mg/d 
was >2 times higher than that in those on bupropion 300mg/d, and, interestingly, three 
times higher than that of those on bupropion 400mg/d. Subjectively, more patients in the 
bupropion group were satisfied with their sexual functioning than in the placebo or 
fluoxetine groups.  
The important issue of potential gender differences in sexual functioning was taken into 
account by two randomised, double blind trails (Kennedy et al., 2006; Thase et al., 2006), 
(total n=473 subjects with MDD but without sexual dysfunction). Thase et al (2006) reported 
that for men, there was a statistically significant difference in sexual functioning in favor of 
bupropion XL for all comparisons with venlafaxine (p0.048); for women, this was also true 
at week 5, week 6, and for the average across weeks 5 to 12 (p0.043). Notably, bupropion 
XL was also superior to venlafaxine XR on the CSFQ subscales for pleasure, desire/frequency, 
desire/interest, arousal, and orgasm throughout the study period. Following an 8-week 
treatment period with either bupropion or paroxetine, Kennedy et al (2006) found that 
women (n=68) in the bupropion group experience significantly higher levels of sexual 
functioning Sexual Functioning (Sex FX) total, p<0.01; desire, p<0.01; arousal, p<0.01; overall 
satisfaction, p<0.01). In men (n=73), the analysis revealed a significant treatment effect by 
visit for Sex FX total (p<0.001), desire (p<0.001), and overall satisfaction (p<0.01). The effect 
was due to a significant decrease in sexual functioning during paroxetine treatment (Sex FX 
total, p<0.002; Desire, p<0.005; Arousal, p<0.005; and overall satisfaction p<0.057); at week 
8 the paroxetine groups displayed a significant deterioration from baseline, on Sex FX total 
(p<0.01), desire (p<0.01), arousal (p<0.05), orgasm (p<0.01), and overall satisfaction 
(p<0.01) scores, whereas no significant change was observed in any of these measures 
across visits in men randomised to the bupropion SR group.  
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Several studies evaluated bupropion’s effectiveness at reducing existing sexual dysfunction: 
four studies measured changes in sexual functioning when subjects were either switched 
from their previous SSRI/SNRI to bupropion monotherapy or bupropion was added to their 
current SSRI treatment plan. Clayton, McGarvey, Abouesh, & Pinkerton (2001) reported 
significant improvements in global CSFQ scores by week 2 in the co-prescribing group 
(SSRI/SNRI+bupropion) and from week 2 to 4 in the monotherapy group (discontinuation 
from SSRI/SNRI to bupropion monotherapy), with gains over baseline maintained by the 8-
week endpoint (p<0.05). A similar pattern was observed on the subscales of sexual desire 
and orgasm, mean scores differing significantly (p<0.05) from baseline to weeks 4 and 8, 
indicating improvement following SSRI discontinuation and the start of bupropion 
monotherapy, but not for co-prescribing. In a later, placebo controlled, double blinded 
study (n=42) by the same group Clayton et al (2004) reported that neither the addition of 
bupropion nor placebo produced a change in CSFQ total scores after 4 weeks; however, 
those co-prescribed bupropion self-reported improved desire and frequency of sexual 
activity (Wilk's F = 5.47, df = 1, p =.024). Dobkin et al (2006) conducted a 10 week open-label 
study of 18 ethnic minority depressed women with poor response to current SSRI treatment 
and hypoactive sexual desire. Compared to baseline measurement, after 8 weeks of 
bupropion monotherapy (i.e. week 10), there were significant improvements in desire 
[F(1,17)=34.86, p<0.001], arousal [F(1,17)=25.99, p<0.001], and orgasm [F(1,17)=20.16, 
p<0.001]. Post-hoc analyses indicated that improvements were observed as early as week 2 
(end of cross-taper) for desire scores [t17=3.94, p=0.001], and at week 4 for arousal 
(t17=5.62, p<0.001) and orgasm scores (t17 = 4.53, p<0.001). More recently, a 12 week 
double blind RCT of 218 women with SSRI-induced sexual dysfunction reported the Female 
Sexual Function Index total score was higher in the bupropion sustained release group (25.9 
(5.12), 95% confidence interval (CI) 22.2–29.4) than in those randomised to placebo co-
prescribing (17.2 (4.9), 95% CI 15.8–20.1) (p = 0.001). In addition, at the end of the trial the 
mean (SD) scores for desire (4.1 (0.7), 95% CI 3.5–4.8; p = 0.001), arousal (4.4 (0.6), 95% CI 
3.7–4.8) (p = 0.01), lubrication (4.4 (0.4), 95% CI 3.3–4.8) (p = 0.001), orgasm (4.4 (0.5), 95% 
CI 3.7–4.7) (p = 0.001), and satisfaction (4.2 (0.7), 95% CI 3.4–4.8) (p = 0.001) were 
significantly higher in the bupropion group (Safarinejad, 2011). 
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Other side-effects 
The majority of identified studies described side effects frequently reported (generally 
defined as occurring at least 5% of patients). Overall, following bupropion treatment, side 
effects experienced were generally of mild to moderate intensity, and the most commonly 
reported were: dry mouth (5% - 34.5%), insomnia (1% - 27.8%), headache (3% - 34%), and 
nausea (7% - 21%). Other adverse events occurring seldom in the literature included 
restlessness, anxiety, constipation, dizziness, nasopharyngitis, and fatigue. Discontinuation 
rates due to adverse events ranged from none to 55%, however, bupropion was not 
significantly different from other antidepressants and in some cases placebo treatments. 
 
Discussion 
This review set out to systematically evaluate and meta-analyse the existing evidence for 
the use of bupropion as an antidepressant. 51 studies were identified, clustering into four 
groups: the sole use of bupropion; bupropion co-prescribing; ‘other’ populations; and side 
effects. Regarding the methodologically more robust data, bupropion showed superiority to 
placebo in most, but not all RCTs; study sizes were generally reasonable, encompassing 
several hundred participants, though follow-up times were typically relatively brief, lasting 
in the range of eight weeks or so. Meta-analysis of trials where sufficient data were 
provided to allow sufficient extraction, produced a result further supporting bupropion in 
this group; however the small number of trials so included means that caution should be 
exerted in interpreting this. Comparator trials generally showed bupropion as having 
equivalent effectiveness to other antidepressants, but a considerable number of studies did 
not have placebo arms, most drugs had few trials (sertraline 5; fluoxetine 2; paroxetine 2; 
venlafaxine 3; and one each for escitalopram, duloxetine, trazadone and nortriptyline); 
furthermore many of the studies are now of considerable age. The RCT by Clayton et al 
(2006) is notable both for its large size (n=785) and its inclusion of a placebo arm in addition 
to bupropion and placebo; however whilst the pooled active drug data were superior to 
placebo, analysis of bupropion alone failed to show separation from placebo. The most 
evaluated head-to-head drug was sertraline, and all trials with placebo arms showed 
bupropion’s superiority to placebo, and equivalence with the comparator drug. 
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Bupropion, arguably, has had a greater role in clinical practice as a co-prescribed 
antidepressant; this may be due to several factors including (in some jurisdictions) limited or 
lack of licensing, a lack of clear evidence or recommendations as a first line drug, and the 
fact that its pharmacodynamics would suggest it might augment existing first line 
medications. This latter factor would appear to be borne out in the studies adding 
bupropion to the highly serotonergic drug (es)citalopram. Data from these trials are 
supportive of bupropion co-prescribing, with the caveat that most were open-label. Results 
from co-prescribing with non-SSRIs are sparse, with a single trial of duloxetine and one of 
venlafaxine: the former had disappointing results, whilst the latter is again marked by an 
open label methodology. It is perhaps the multi-medication trials that have most raised 
bupropion in clinicians’ awareness, notably the STAR*D work that has been widely reported. 
STAR*D supports the addition of bupropion as an intervention of value, but with the caveats 
that overall outcomes in TRD are disappointing, and numbers going into remission are low in 
all secondary treatment arms. The study emphasises the variation and difficulty in 
predicting individuals’ responses. The work by Blier et al (2010) is consistent with this, albeit 
in a trial with far fewer participants. Both of these support the principle of co-prescribing, 
but highlight that bupropion, whilst a reasonable option, is not superior to other drug 
choices. 
Data from the ‘other’ section are interesting, but generally marked by a dearth of research. 
Positive results were seen in bipolar depression, older adults, seasonal affective disorder, a 
dysthymia, but considerable caution is required in interpretation due to the general lack of 
studies in this area. Of this section the work by Modell et al (2005) on SAD is noteworthy 
due to its large size (n=1042), randomised nature, and the fact it was undertaken 
prophylactically in asymptomatic individuals. Their results support the prophylactic 
prescribing of bupropion in SAD, though the absolute numbers of those relapsing were low 
in both groups, which raises the issue of benefit:risk ratios in prescribing medications. 
With regards to side effects, bupropion is generally a well-tolerated drug, the type, severity, 
and frequency of problems fitting with that of most SSRIs. There are two clear notable 
differences however; weight change and sexual functioning. The evidence is in favour of 
bupropion producing no weight gain, and typically weight loss, and that it can improve 
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sexual functioning in depressed individuals. This is potentially very important, as these are 
considerable drug and illness induced difficulties for many with MDD. 
Interpreting this broad literature, several challenges emerge. As has been mentioned, the 
methodology of many studies can be questioned; there were many open-label trials, and 
many of the head-to-head and multi-drug studies did not have placebo arms. Inevitably 
cross-comparison between different head-to-head drugs is difficult, not least as some drugs 
have single trials, some of which are almost twenty years old. Follow-up periods were 
typically brief, in the order of a couple of months or so. However, in general where response 
to an antidepressant occurs, it tends to be within such a timeframe (Fornaro et al., 2014). 
Regarding participants, there was a wide range of inclusion and exclusion criteria, not least 
in defining (or not defining) if individuals were treatment refractory, and indeed no clear 
consensus on what that meant. This factor is critically important if one considers that one of 
the major outcomes of STAR*D was showing how poor responses are in general as one 
moves through sequential stages of depression management. As such, much bupropion 
prescribing is thus potentially in individuals fundamentally more refractory to 
pharmacological intervention, but the variation in study criteria makes this very difficult to 
elucidate as a factor; work on first episode and treatment naïve individuals would be 
welcomed. 
Zimmerman et al (2004) reported that the targeting of specific symptoms and the desire to 
avoid certain side effects were the most frequently given reasons expressed by a small US 
sample (n=10) of psychiatrists for choosing bupropion, namely hypersomnia, hyperphagia 
and fatigue; high levels of anxiety, irritability, poor sleep and appetite were significantly less 
often cited as a reason for prescribing. For approximately half of the patients, the desire to 
avoid weight gain or sexual dysfunction was reported as a reason for choosing bupropion. 
The issue of bupropion’s novel pharmacology is also one of the primary reasons behind 
many of co-prescribing studies, with the consideration that its differing mechanism of action 
might compliment – or enhance – another drug. This is a complex and incompletely 
understood area, and there are several possibilities, none yet clearly proven. The first is a 
potential pharmacokinetic effect wherein co-prescribing will change the plasma protein 
binding and availability of the drugs; thus additional effects might arise solely through an 
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effective increase in the unbound and active level of one or other – or both – drugs. A 
second possibility is that there is a pharmacodynamic additive effect through the use of two 
compounds, each producing different pharmacological effects. Finally it is further possible 
that there is a synergistic effect, with the combined compounds pharmaco-kinetically 
and/or -dynamically producing an effect greater than the sum of their individual actions. 
Problematically, there are few RCTs, and fewer of sufficient size or duration, that might 
allow elucidation of these factors; an issue compounded by the earlier mentioned variable 
population responses. It is just as possible in open label work that the effective factor is 
time; a second drug is added, and a response is seen, but this is, in fact, just a delayed 
response to the first compound.  
Following on from this, depressive disorders are becoming ever more to be seen as 
fundamentally heterogeneous conditions with as yet incompletely understood but highly 
complex pathway disorders involving numerous gene and environmental interactions 
(Koutsouleris et al., 2015). In psychosis studies there has been an argument to 
reconceptualise ‘the schizophrenias’ (Arnedo et al., 2015), and we would argue that ‘the 
depressions’ are equally likely. As such, the bupropion data face a similar problem to that of 
the wider pharmacological literature; the critical question – that does not have an answer at 
this time –in whom and when might bupropion work, rather than the typical cruder class-
effect query of “is it effective in depression?” This is of particular interest with bupropion 
given its differing mechanism of action that is primarily noradrenergic and dopaminergic 
(but no serotonergic) effects, raising the interesting question about whether it might target 
specific symptoms in depression, or certain types of depression.  
With specific consideration of the bupropion literature, there are some interesting findings 
in this regard, though the field is nascent. The study by Weissman et al (2015), in depressed 
mothers, is a thought-provoking example. Whilst bupropion was as effective as 
escitalopram, it was less effective with regards to their children’s mental health; 
subanalyses showed that escitalopram was more effective with regards to treating ‘negative 
affectivity’ (guilt, irritability, fear/anxiety), which the authors posit has a more serotonergic 
underpinning. Another domain specific negative finding was the work by Grunebaum et al 
(2012) which found bupropion less effective at managing suicidal feelings than paroxetine; 
this may fit with a literature suggesting that serotonergic dysfunctioning is associated with 
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suicidality. Fornaro et al (2014) intentionally co-prescribed bupropion with duloxetine in a 
cohort with atypical depression (carbohydrate craving, hypersomnia etc.) on the basis that 
bupropion’s additional dopaminergic and noradrenergic functioning might provide 
additional therapeutic gains, though this was not borne out in the (relatively small) sample. 
Conversely, Mohan et al (2009), in their study of bupropion co-prescribing with 
escitalopram, showed that so-called ‘melancholic features’ of depression were more 
effectively treated by bupropion.  
Of the studies that have explored the possibility of bupropion producing a more distinct 
pattern of changes across specific symptom dimensions, differential response to bupropion 
has been identified with regards to negative affect. One study reported in this review in the 
context of HAM-D scores, also used a dimensional assessment of mood based on the 
tripartite model of mood disorders (Clark & Watson, 1991) administering the mood and 
anxiety symptom questionnaire (MASQ AD Scale) (Tomarken et al., 2004). The authors 
reported that bupropion exerted a more robust effect on the positive affect dimension 
(energy, motivation, enjoyment) but not negative affect (general distress and somatic 
anxiety). Interestingly, during the earlier phase when bupropion was dosed at a lower range 
(100-300mg/d) a stronger effect was observed on the affectively negative dimensions, but 
later within the open label phase where bupropion was dosed at higher range (300-
400mg/d) a notably higher effect was observed on the affectively positive dimensions, 
perhaps suggesting a dose dependant relationship or due to a longer time in treatment. In a 
closer examination of the effects of bupropion on negative affect, through a post hoc 
analysis of monotherapy treatment (bupropion vs. escitalopram) in patients with MDD 
(n=163), Gerra et al (2014) reported that whilst response to escitalopram did not differ 
significantly between low- and high- negative affect patients, bupropion was significantly 
more effective for patients with low negative affect than high negative affect (p<0.03). 
Conversely, escitalopram was significantly more effective than bupropion for high negative 
affect patients (p=0.017). This suggests that bupropion may be more suitable in the 
treatment of the core components of depression rather than for the commonly 
encountered illness-associated anxiety.  
The issue of bupropion’s lack of a licence is problematic in some jurisdictions, including the 
United Kingdom. The existing evidence would support bupropion’s addition to the 
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pharmacological armamentarium; however the burdens of obtaining a European licence are 
bureaucratically and financially considerable. For a pharmaceutical company, this may 
present an unappealing prospect; having gone through this process, it is likely to be some 
time before guidelines or local policies promote bupropion, at such point probably 
recommending it as a third, fourth, fifth (or worse) choice of drug. The head-to-head data 
do not suggest it should have a higher role than this, but it means that financial returns are 
likely to be scant in an already bloated market-place, acting as a further disincentive to 
obtain a licence to market this medication. However, this presents clinicians with a problem; 
whilst most research shows rough equivalence between various antidepressants, 
undoubtedly individual responses vary considerably, and there are, and will be, patients 
who will respond well to bupropion, perhaps better than to other compounds. Of course a 
current scientific frustration – by no means limited to bupropion – is prospectively 
identifying such individuals, but the field of pharmacogenomics remains in its infancy, with 
disappointing results thus far (Penn & Tracy, 2012). However, the lack of a licence means 
that many clinicians (and potentially patients) will be hesitant to try the drug, and may face 
further problems such as having difficulties having such prescriptions continued in primary 
care. 
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